Cargando…

Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols

Rationale: lactose is the only FDA-approved carrier for dry powder inhaler (DPI) formulations in the US. Lactose carrier-based DPI products are contraindicated in patients with a known lactose allergy. Hence, inhaler formulations without lactose will benefit lactose allergic asthmatics. Objectives:...

Descripción completa

Detalles Bibliográficos
Autores principales: Muralidharan, Priya, Mallory, Evan K., Malapit, Monica, Phan, Hanna, Ledford, Julie G., Hayes, Don, Mansour, Heidi M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689944/
https://www.ncbi.nlm.nih.gov/pubmed/33391731
http://dx.doi.org/10.1039/d0ra07203f
_version_ 1783613966876934144
author Muralidharan, Priya
Mallory, Evan K.
Malapit, Monica
Phan, Hanna
Ledford, Julie G.
Hayes, Don
Mansour, Heidi M.
author_facet Muralidharan, Priya
Mallory, Evan K.
Malapit, Monica
Phan, Hanna
Ledford, Julie G.
Hayes, Don
Mansour, Heidi M.
author_sort Muralidharan, Priya
collection PubMed
description Rationale: lactose is the only FDA-approved carrier for dry powder inhaler (DPI) formulations in the US. Lactose carrier-based DPI products are contraindicated in patients with a known lactose allergy. Hence, inhaler formulations without lactose will benefit lactose allergic asthmatics. Objectives: to rationally design and develop lactose carrier-free dry powder inhaler formulations of fluticasone propionate and salmeterol xinafoate that will benefit people with known lactose allergy. The study also aims at improving the aerosol deposition of the dry powder formulation through advanced particle engineering design technologies to create inhalable powders consisting of nanoparticles/microparticles. Methods: advanced DPI nanoparticle/microparticle formulations were designed, developed and optimized using organic solution advanced closed-mode spray drying. The co-spray dried (co-SD) powders were comprehensively characterized in solid-state and in vitro comparative analysis of the aerodynamic performance of these molecularly mixed formulations was conducted with the marketed formulation of Advair® Diskus® interactive physical mixture. Measurements and main results: comprehensive solid-state physicochemical characterization of the powders showed that the engineered co-SD particles were small and spherical within the size range of 450 nm to 7.25 μm. Improved fine particle fraction and lower mass median aerodynamic diameter were achieved by these DPI nanoparticles/microparticles. Conclusions: this study has successfully produced a lactose-free dry powder formulation containing fluticasone propionate and salmeterol xinafoate with mannitol as excipient engineered as inhalable DPI nanoparticles/microparticles by advanced spray drying. Further, co-spray drying with mannitol and using Handihaler® device can generate higher fine particle mass of fluticasone/salmeterol. Mannitol, a mucolytic agent and aerosol performance enhancer, is a suitable excipient that can enhance aerosol dispersion of DPIs.
format Online
Article
Text
id pubmed-7689944
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-76899442020-12-30 Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols Muralidharan, Priya Mallory, Evan K. Malapit, Monica Phan, Hanna Ledford, Julie G. Hayes, Don Mansour, Heidi M. RSC Adv Chemistry Rationale: lactose is the only FDA-approved carrier for dry powder inhaler (DPI) formulations in the US. Lactose carrier-based DPI products are contraindicated in patients with a known lactose allergy. Hence, inhaler formulations without lactose will benefit lactose allergic asthmatics. Objectives: to rationally design and develop lactose carrier-free dry powder inhaler formulations of fluticasone propionate and salmeterol xinafoate that will benefit people with known lactose allergy. The study also aims at improving the aerosol deposition of the dry powder formulation through advanced particle engineering design technologies to create inhalable powders consisting of nanoparticles/microparticles. Methods: advanced DPI nanoparticle/microparticle formulations were designed, developed and optimized using organic solution advanced closed-mode spray drying. The co-spray dried (co-SD) powders were comprehensively characterized in solid-state and in vitro comparative analysis of the aerodynamic performance of these molecularly mixed formulations was conducted with the marketed formulation of Advair® Diskus® interactive physical mixture. Measurements and main results: comprehensive solid-state physicochemical characterization of the powders showed that the engineered co-SD particles were small and spherical within the size range of 450 nm to 7.25 μm. Improved fine particle fraction and lower mass median aerodynamic diameter were achieved by these DPI nanoparticles/microparticles. Conclusions: this study has successfully produced a lactose-free dry powder formulation containing fluticasone propionate and salmeterol xinafoate with mannitol as excipient engineered as inhalable DPI nanoparticles/microparticles by advanced spray drying. Further, co-spray drying with mannitol and using Handihaler® device can generate higher fine particle mass of fluticasone/salmeterol. Mannitol, a mucolytic agent and aerosol performance enhancer, is a suitable excipient that can enhance aerosol dispersion of DPIs. The Royal Society of Chemistry 2020-11-17 /pmc/articles/PMC7689944/ /pubmed/33391731 http://dx.doi.org/10.1039/d0ra07203f Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Muralidharan, Priya
Mallory, Evan K.
Malapit, Monica
Phan, Hanna
Ledford, Julie G.
Hayes, Don
Mansour, Heidi M.
Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols
title Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols
title_full Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols
title_fullStr Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols
title_full_unstemmed Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols
title_short Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols
title_sort advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689944/
https://www.ncbi.nlm.nih.gov/pubmed/33391731
http://dx.doi.org/10.1039/d0ra07203f
work_keys_str_mv AT muralidharanpriya advanceddesignanddevelopmentofnanoparticlemicroparticledualdrugcombinationlactosecarrierfreedrypowderinhalationaerosols
AT malloryevank advanceddesignanddevelopmentofnanoparticlemicroparticledualdrugcombinationlactosecarrierfreedrypowderinhalationaerosols
AT malapitmonica advanceddesignanddevelopmentofnanoparticlemicroparticledualdrugcombinationlactosecarrierfreedrypowderinhalationaerosols
AT phanhanna advanceddesignanddevelopmentofnanoparticlemicroparticledualdrugcombinationlactosecarrierfreedrypowderinhalationaerosols
AT ledfordjulieg advanceddesignanddevelopmentofnanoparticlemicroparticledualdrugcombinationlactosecarrierfreedrypowderinhalationaerosols
AT hayesdon advanceddesignanddevelopmentofnanoparticlemicroparticledualdrugcombinationlactosecarrierfreedrypowderinhalationaerosols
AT mansourheidim advanceddesignanddevelopmentofnanoparticlemicroparticledualdrugcombinationlactosecarrierfreedrypowderinhalationaerosols